Kinaset Therapeutics Doses First Patient in Phase 2b Trial of Frevecitinib for Severe Asthma
Kinaset Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative inhaled therapies for serious respiratory diseases, has announced the dosing of the first patient in its Phase 2b clinical trial evaluating frevecitinib, an investigational inhaled pan-Janus kinase (JAK) inhibitor, for the treatment of severe asthma. The milestone marks a significant advancement in the clinical development of the company’s lead drug candidate and represents an important step toward addressing the unmet needs of patients whose asthma remains inadequately controlled despite receiving current standard therapies.
The Phase 2b study, known as PANAIRAMA, will assess the efficacy, safety, pharmacokinetics, and optimal dosing of frevecitinib in patients with severe asthma who continue to experience symptoms while being treated with medium- to high-dose inhaled corticosteroids (ICS) combined with long-acting beta agonists (LABAs). Despite these widely used maintenance therapies, many individuals continue to experience frequent asthma attacks, persistent airway inflammation, impaired lung function, and a reduced quality of life, highlighting the need for more effective treatment options.
Frevecitinib has been developed as a novel inhaled therapy designed to target multiple inflammatory pathways involved in asthma while minimizing systemic drug exposure. If successful, the therapy could represent a first-in-class and potentially best-in-class inhaled pan-JAK inhibitor capable of addressing a broader range of asthma phenotypes than currently available treatments.
Advancing a Novel Approach to Asthma Treatment
Asthma is one of the world’s most common chronic respiratory diseases, affecting hundreds of millions of people globally. It is characterized by chronic inflammation of the airways, leading to symptoms such as wheezing, shortness of breath, chest tightness, coughing, and episodes of airway obstruction.
Although many patients achieve good disease control with inhaled corticosteroids and bronchodilator therapies, a substantial proportion continue to experience uncontrolled asthma despite receiving guideline-recommended treatment.
Patients with severe asthma often face repeated exacerbations, emergency department visits, hospitalizations, and progressive declines in lung function. Persistent inflammation can significantly impact daily activities, work productivity, and overall quality of life.
Kinaset Therapeutics is developing frevecitinib with the goal of providing an alternative therapeutic approach capable of targeting multiple inflammatory mechanisms responsible for asthma progression.
The PANAIRAMA Phase 2b Clinical Trial
The newly initiated PANAIRAMA study has been designed as a comprehensive Phase 2b clinical trial intended to identify the most effective dose of frevecitinib for future late-stage clinical development.
The study is a:
- Randomized clinical trial
- Double-blind investigation
- Placebo-controlled study
- Dose-ranging trial
Researchers will evaluate three different dose levels of frevecitinib to determine which regimen provides the best balance of efficacy and safety.
In addition to measuring treatment effectiveness, investigators will assess:
- Safety and tolerability
- Pharmacokinetic characteristics
- Dose-response relationships
- Clinical outcomes in severe asthma patients
The information generated during the study will help establish the optimal dosing strategy for future pivotal clinical trials that may support regulatory submissions.
International Patient Enrollment
PANAIRAMA will recruit participants from multiple clinical research centers across the United States as well as several international study sites.
The broad geographic enrollment strategy is intended to include a diverse patient population while generating robust clinical data across different healthcare settings.
The study focuses specifically on patients with severe asthma whose disease remains inadequately controlled despite treatment with medium- to high-dose inhaled corticosteroids combined with long-acting beta agonists.
These individuals represent a population with substantial unmet medical needs, as many continue to experience symptoms despite receiving currently available maintenance therapies.
A First-in-Class Inhaled Pan-JAK Inhibitor
Frevecitinib distinguishes itself from other investigational asthma therapies through its unique mechanism of action.
According to Kinaset Therapeutics, the investigational medicine is currently the only inhaled pan-JAK inhibitor in clinical development that simultaneously targets:
- JAK1
- JAK2
- JAK3
- TYK2
The Janus kinase family plays an essential role in transmitting signals from multiple cytokines involved in immune regulation and inflammatory responses.
By inhibiting all four major JAK family members, frevecitinib is designed to interrupt numerous inflammatory signaling pathways that contribute to asthma.
This broad activity may allow the therapy to address diverse forms of airway inflammation more effectively than treatments targeting a single pathway.
Targeting Both Th2 and Th1 Inflammation
One of the major scientific rationales behind frevecitinib involves its ability to target both Type 2 helper T-cell (Th2) and Type 1 helper T-cell (Th1) inflammatory pathways.
Most currently approved biologic therapies for severe asthma primarily target Type 2 inflammation.
While these therapies have transformed treatment for many patients with eosinophilic asthma, they may be less effective for individuals whose disease is driven by alternative inflammatory mechanisms.
Frevecitinib has the potential to suppress inflammatory signaling involved in both Th2-driven and Th1-driven disease.
This broader immunologic activity could expand treatment options for patients with:
- Eosinophilic asthma
- Mixed inflammatory asthma
- Non-eosinophilic asthma
The latter remains an area where effective targeted therapies are relatively limited.
Delivering Therapy Directly to the Lungs
A distinguishing feature of frevecitinib is its inhaled route of administration.
Instead of being delivered systemically through oral tablets or injections, the medication is inhaled directly into the lungs.
This localized delivery strategy offers several potential advantages.
By concentrating therapeutic drug levels within the respiratory tract, frevecitinib aims to:
- Maximize anti-inflammatory activity in lung tissue
- Reduce systemic drug exposure
- Lower the risk of systemic side effects
- Improve treatment tolerability
Because systemic JAK inhibitors have sometimes been associated with important safety considerations, minimizing systemic drug concentrations has become an important goal in developing inhaled JAK therapies.
Addressing Non-Eosinophilic Asthma
A particularly important aspect of frevecitinib’s development is its potential role in non-eosinophilic asthma.
Unlike eosinophilic asthma, which is characterized by elevated eosinophil levels and responds well to several available biologic therapies, non-eosinophilic asthma often involves different inflammatory pathways that remain more difficult to target.
Patients with non-eosinophilic disease frequently continue experiencing persistent symptoms despite available treatment options.
By inhibiting multiple cytokine signaling pathways simultaneously, frevecitinib may provide therapeutic benefit for this underserved patient population.
If confirmed in clinical studies, this broader applicability could differentiate frevecitinib from many currently available biologic therapies.
Encouraging Phase 1 Results
The decision to advance frevecitinib into Phase 2b development follows encouraging findings from the company’s earlier Phase 1 clinical program.
During Phase 1 evaluation, the investigational therapy demonstrated clinically meaningful reductions in fractional exhaled nitric oxide (FeNO).
FeNO is widely recognized as a biomarker of airway inflammation and is frequently used to assess inflammatory activity in asthma.
Reductions in FeNO may indicate decreased airway inflammation and improved disease control.
Importantly, beneficial reductions were observed across several respiratory conditions, including:
- Mild asthma
- Moderate-to-severe asthma
- Chronic obstructive pulmonary disease (COPD)
These findings provided early evidence that frevecitinib may exert meaningful anti-inflammatory effects within the lungs.
Favorable Pharmacokinetic Profile
Phase 1 studies also generated encouraging pharmacokinetic data.
Researchers observed dose-proportional pharmacokinetics, indicating that systemic drug exposure increased predictably with increasing inhaled doses.
Perhaps more importantly, measured plasma concentrations remained below pharmacologically active systemic levels.
This finding supports the intended design of frevecitinib as a locally acting inhaled therapy rather than a systemically active medication.
Maintaining low systemic exposure may reduce the likelihood of systemic adverse effects while preserving therapeutic concentrations within lung tissue.
Positive Early Safety Observations
Kinaset also reported encouraging safety findings during its Phase 1 development program.
To date, investigators have observed:
- No significant systemic safety concerns
- No major local tolerability issues
- Favorable overall safety profile
Although larger and longer clinical trials remain necessary to fully establish safety, these early observations provide an important foundation for continued clinical development.
The Phase 2b study will further evaluate both safety and tolerability across a larger patient population receiving repeated treatment.
Executive Perspective
Commenting on the initiation of the Phase 2b study, Dr. Christopher O’Brien, Chief Medical Officer of Kinaset Therapeutics, described the dosing of the first patient as an important milestone in frevecitinib’s clinical development.
According to O’Brien, the encouraging results generated during Phase 1 support the belief that frevecitinib has the potential to become both a first-in-class and best-in-class inhaled therapy for patients whose asthma remains inadequately controlled despite current standard treatments.
He emphasized that by simultaneously targeting Th2- and Th1-mediated inflammatory pathways, frevecitinib may provide therapeutic benefit across a broader spectrum of asthma patients than currently available options, potentially improving outcomes beyond existing standards of care.
The initiation of the PANAIRAMA Phase 2b trial marks a significant advancement in the development of frevecitinib and reflects Kinaset Therapeutics’ commitment to addressing persistent unmet needs in severe asthma. By combining broad inhibition of JAK1, JAK2, JAK3, and TYK2 with localized inhaled delivery, the investigational therapy is designed to suppress multiple inflammatory pathways while minimizing systemic drug exposure.
Building on encouraging Phase 1 findings demonstrating reductions in airway inflammation, predictable pharmacokinetics, and a favorable early safety profile, the Phase 2b study will help determine the optimal dosing regimen for future pivotal trials. If successful, frevecitinib could become an important new treatment option for patients with severe asthma—including those with non-eosinophilic disease who currently have limited targeted therapies available.
As enrollment progresses across international clinical sites, the trial is expected to generate critical data that will guide the next stage of clinical development and further evaluate the therapy’s potential to improve outcomes for patients living with difficult-to-control asthma.
About frevecitinib
Frevecitinib is a novel, potential best-in-class inhaled pan-JAK inhibitor (JAK1, JAK2, JAK3, TYK2) that is being developed as a maintenance treatment for patients whose asthma remains inadequately controlled on standard inhaled therapies. With its broad mechanism of action, frevecitinib has the potential to address multiple inflammatory pathways implicated in asthma, including both Th2- and Th1-driven disease, and may help address an important limitation of existing treatment options.
Frevecitinib was designed through an integrated chemistry and formulation strategy intended to overcome drug delivery challenges that have limited prior attempts to develop inhaled JAK inhibitors. The molecule is formulated as a dry powder for inhalation and is designed to deliver pharmacologically active concentrations directly to lung tissue while minimizing systematic exposure. Unlike other inhaled JAK inhibitor candidates, frevecitinib is intended to deliver therapeutic doses through a single actuation.
About Kinaset Therapeutics, Inc.
Kinaset Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel inhaled therapies for patients with severe respiratory diseases. The Company’s lead program, frevecitinib, is a differentiated inhaled pan-JAK inhibitor designed to deliver broad anti-inflammatory activity directly to the lungs while limiting systemic exposure. Frevecitinib is being developed for patients with serious respiratory conditions including asthma that remains inadequately controlled by standard inhaled maintenance therapies. For more information, visit the Company’s website.